ICU Medical (NASDAQ:ICUI) Posts Earnings Results, Beats Estimates By $0.30 EPS

Key Points

• ICU Medical beat Q3 estimates: Adjusted EPS was $2.44, $0.30 above consensus, while revenue of $556.22 million topped forecasts and rose 4.4% year over year.
• Growth and outlook were solid: Organic revenue rose 5%, adjusted EBITDA increased 8%, and management expects full-year adjusted EPS and EBITDA to finish near the high end of its guidance ranges.
• Operational challenges remain: Integration-related logistics issues disrupted international deliveries and contributed to a 10% organic decline in Vital Care; management expects most problems to be resolved in Q4.

ICU Medical (NASDAQ:ICUI - Get Free Report) announced its earnings results on Thursday. The medical instruments supplier reported $2.44 earnings per share for the quarter, topping analysts' consensus estimates of $2.14 by $0.30, FiscalAI reports. The company had revenue of $556.22 million for the quarter, compared to analyst estimates of $552.03 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%. The firm's quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the company earned $2.03 earnings per share.

Here are the key takeaways from ICU Medical's conference call:

• Q3 revenue was $556 million, up 5% organically, while adjusted EBITDA rose 8% to $114 million and adjusted EPS increased 20% to $2.44. Consumables and Infusion Systems each posted record sales.
• Management expects full-year adjusted EBITDA of $415 million–$435 million and adjusted EPS of $8.60–$9.00 to finish toward the high end of its existing ranges. Adjusted gross margin reached 42%, and the company reiterated its goal of reaching 43% by the end of 2027.
• Free cash flow was $83 million in Q3, supporting about $80 million of debt repayment and bringing net leverage to 2.0x. However, year-to-date cash flow benefited from tariff refunds and lower capital spending, and management expects Q4 free cash flow to be lower than Q3.
• Integration-related logistics problems disrupted international deliveries and weighed on Vital Care, which declined 10% organically in Q3; management expects a larger full-year decline for the segment. It said most of the operational issues should be resolved in Q4.
• ICU Medical reported progress on its product pipeline, including approvals for infusion pumps in Canada and Europe and plans to file a revised Medfusion 5000 syringe-pump application in the coming weeks. Several Consumables launches are planned for 2027, though the company said pump-install-base replacement is likely to unfold over 2027–2029.

ICU Medical Price Performance

NASDAQ ICUI traded up $4.46 during midday trading on Friday, hitting $172.11. The company had a trading volume of 464,850 shares, compared to its average volume of 283,141. The firm has a 50-day moving average price of $162.97 and a 200-day moving average price of $149.18. The company has a market capitalization of $4.30 billion, a PE ratio of 145.86, a P/E/G ratio of 2.17 and a beta of 0.88. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56. ICU Medical has a twelve month low of $113.37 and a twelve month high of $192.85.

Insider Activity at ICU Medical

In related news, COO Christian Voigtlander sold 8,929 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $182.93, for a total value of $1,633,381.97. Following the completion of the transaction, the chief operating officer owned 37,377 shares of the company's stock, valued at $6,837,374.61. The trade was a 19.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Virginia Sanzone sold 4,856 shares of the company's stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $168.69, for a total transaction of $819,158.64. Following the sale, the vice president directly owned 14,604 shares of the company's stock, valued at $2,463,548.76. This represents a 24.95% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 21,830 shares of company stock worth $3,905,003 in the last quarter. 2.10% of the stock is currently owned by corporate insiders.

Key Stories Impacting ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q3 results exceeded expectations: ICU Medical reported earnings of $2.44 per share versus the $2.14 consensus estimate, while revenue of $556.22 million also topped forecasts. Revenue rose 4.4% year over year, and earnings increased from $2.03 per share a year earlier. Zacks Q3 earnings report
• Positive Sentiment: Full-year outlook remains solid: The company reaffirmed its 2026 guidance and expects results at the high end of its forecast range, supporting confidence in its near-term performance. Q3 results and guidance
• Positive Sentiment: Analyst targets moved higher: Piper Sandler raised its target to $200 and maintained an Overweight rating; KeyCorp lifted its target to $189 and also kept an Overweight rating. BTIG reiterated its Buy rating and $200 target. These endorsements signal continued analyst confidence in potential upside. BTIG rating update
• Neutral Sentiment: Management will present at the Jefferies Global Healthcare Conference in London on November 15–18. The appearance may provide an opportunity to discuss the business, but no new financial information was announced. Conference announcement

Wall Street Analyst Weigh In

Several research analysts have weighed in on ICUI shares. Weiss Ratings upgraded ICU Medical from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, October 8th. Piper Sandler upped their price target on shares of ICU Medical from $195.00 to $200.00 and gave the company an "overweight" rating in a research note on Friday. Zacks Research lowered shares of ICU Medical from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 28th. Raymond James Financial reiterated a "strong-buy" rating and issued a $200.00 price objective on shares of ICU Medical in a research note on Friday, August 7th. Finally, Needham & Company LLC boosted their price objective on shares of ICU Medical from $165.00 to $187.00 and gave the company a "buy" rating in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $195.20.

About ICU Medical

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company's portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira's infusion systems business in 2017 and Smiths Medical in 2022.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.